Prognosis
Moderna Offers U.S. Fail-Safe on Vaccines If Pfizer Falls Short
- Government has option for 400 million doses at $16.50 each
- Added doses could roll out starting in April, Moderna says
A participant in a Phase 3 COVID-19 vaccine clinical trial sponsored by Moderna gets a shot during the trial.
Photographer: Paul Hennessy/APThis article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
Moderna Inc. could offer a fail-safe option that will allow the U.S. to get enough Covid-19 shots to inoculate most Americans if the government can’t reach an agreement to quickly buy more vaccine from Pfizer Inc., which plans to honor its contracts with other countries.